MedTrace Logo

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

NCT04593927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 451

Last updated 2024-02-12

No results posted yet for this study

Summary

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

Conditions

  • Secondary Progressive Multiple Sclerosis (SPMS)

Interventions

DRUG

Mayzent

There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2023-08-30
Completion
2023-08-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04593927 on ClinicalTrials.gov